인테그린 억제제를 사용한 간 질환의 조합 치료

• Main Authors: ANDERSON KRAIG, BAILEY CHRISTOPHER, COOPER NICOLE, BOSE AVIRUP, KIRKLAND SUSAN, REILLY MAUREEN, LEFTHERIS KATERINA, HULL JOHANNES, UKOMADU CHINWEIKE, GREENBAUM LINDA, CHA JACOB, TARSA PETER, FINKELSTEIN DARREN
• Format: Patent
• Language: Korean
• Published: 01.09.2022
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

본 발명은 간 질환 또는 장애를 예방하거나 지연시키거나 치료하기 위한 αVβ1 인테그린 억제제 및 적어도 1종의 추가 치료제를 포함하는 약제학적 조합물을 제공한다. 적어도 1종의 추가 치료제는 파르네소이드 X 수용체(FXR) 작용제일 수 있다. 예를 들어, 약제학적 조합물은 (S)-2-(4-메틸테트라하이드로-2H-피란-4-카복사미도)-9-(5,6,7,8-테트라하이드로-1,8-나프티리딘-2-일)노난산(화합물 1) 및 2-[3-({5-사이클로프로필-3-[2-(트리플루오로메톡시)페닐]-1,2-옥사졸-4-일}메톡시)-8-아자바이사이클로[3.2.1]옥탄-8-일]-4-플루오로-1,3-벤조티아졸-6-카복실산(트로피펙소)을 포함한다. The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).